Trial Profile

Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sunitinib (Primary)
Indications Renal cancer
Focus Biomarker; Therapeutic Use
Acronyms SUVEGIL

Most Recent Events

22 Mar 2018 Results assessing effect of angiogenic treatment on VE cadherin post translational modifications using patient data from SUVEGIL and TORAVA trials published in the British Journal of Cancer
29 Aug 2017 Results (n=99) of SUVEGIL and TORAVA trials ,published in the British Journal of Cancer.
18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com